Arundathy N. Pandite - Jan 10, 2024 Form 4 Insider Report for Shattuck Labs, Inc. (STTK)

Role
Chief Medical Officer
Signature
/s/ Andrew R. Neill, Attorney-in-fact for Arundathy N. Pandite
Stock symbol
STTK
Transactions as of
Jan 10, 2024
Transactions value $
-$30,139
Form type
4
Date filed
1/16/2024, 04:31 PM
Previous filing
Jan 27, 2023
Next filing
Jan 31, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction STTK Common Stock Award $0 +46.5K +26.44% $0.00 222K Jan 10, 2024 Direct F1
transaction STTK Common Stock Tax liability -$30.1K -2.99K -1.34% $10.09 219K Jan 10, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STTK Stock Option (Right to Buy) Award $0 +93K $0.00 93K Jan 10, 2024 Common Stock 93K $10.09 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Consists of 46,475 restricted stock units, which will vest in four equal annual installments beginning on January 10, 2025, subject to the Reporting Person's continued service to the Issuer.
F2 This option represents a right to purchase a total of 92,950 shares of the Issuer's common stock, one quarter of which will vest on January 10, 2025, with the remaining three quarters vesting in equal monthly installments through January 10, 2028, subject to the Reporting Person's continued service to the Issuer.